CLEC2D抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD141 mouse mAb (green) and negative control (red).    

  
  

CLEC2D (C-type lectin domain family 2 member D) is a transmembrane protein belonging to the C-type lectin receptor family, primarily expressed on immune cells such as natural killer (NK) cells, γδ T cells, and subsets of CD8+ T cells. It plays a role in immune regulation by interacting with ligands like LLT1 (CLEC2D’s canonical ligand) or other cell-surface molecules, modulating cytotoxic activity and cytokine production. CLEC2D contains an extracellular C-type lectin-like domain and an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM), suggesting its involvement in inhibitory signaling pathways. Dysregulation of CLEC2D has been implicated in diseases such as cancer, autoimmune disorders, and viral infections, where it may either suppress anti-tumor immunity or contribute to immune tolerance.

Antibodies targeting CLEC2D are research tools or potential therapeutics designed to block or modulate its interactions. For example, antagonistic antibodies may enhance NK cell-mediated cytotoxicity by disrupting CLEC2D-LLT1 binding, thereby counteracting immune suppression in tumors. Conversely, agonistic antibodies might exploit CLEC2D’s inhibitory signals to dampen excessive inflammation in autoimmune conditions. Current studies focus on characterizing CLEC2D’s ligand specificity, tissue distribution, and downstream signaling to refine antibody design. Challenges include ensuring specificity and minimizing off-target effects due to structural similarities among C-type lectin family members. Preclinical models are evaluating CLEC2D antibodies for efficacy in cancer immunotherapy and immune modulation, highlighting its dual role as a checkpoint molecule. Further research aims to optimize antibody affinity, isotype selection, and combination therapies for clinical translation.